How to Get Rezdiffra (Resmetirom) in Montana

What Rezdiffra Treats and Why Montana Patients Need Access

Rezdiffra is the first drug the FDA approved specifically for metabolic dysfunction-associated steatohepatitis (MASH), formerly called non-alcoholic steatohepatitis (NASH). The approval, granted on March 14, 2024, covers adults with MASH and moderate to advanced liver fibrosis, staged F2 or F3 on biopsy or validated noninvasive testing.

Montana has roughly 1.1 million residents, many of whom live in rural counties hours from the nearest gastroenterologist or hepatologist. The state's obesity prevalence sits above 30%, and the CDC estimates that MASH affects between 1.5% and 6.5% of the U.S. adult population. For Montanans with progressing fibrosis, Rezdiffra represents the only FDA-approved pharmacotherapy that has demonstrated fibrosis improvement on histology.

In the MAESTRO-NASH trial (N=966), resmetirom 80 mg produced MASH resolution without worsening of fibrosis in 25.9% of patients at 52 weeks versus 9.7% on placebo. The 100 mg arm achieved 29.9% resolution [1]. A fibrosis improvement endpoint (at least one stage with no worsening of the NAFLD Activity Score) was met by 24.2% of the 80 mg group and 25.9% of the 100 mg group, compared with 14.2% on placebo [1]. These numbers matter because fibrosis stage is the strongest histologic predictor of liver-related mortality, as confirmed in a meta-analysis of paired-biopsy studies published in Gastroenterology (2017).

The AASLD practice guidance (2023) recommends pharmacotherapy for patients with biopsy-confirmed or noninvasively staged MASH and significant fibrosis (F2 or higher). Rezdiffra fits squarely in that recommendation.

Step-by-Step Prescription Pathway in Montana

Getting a Rezdiffra prescription in Montana follows a four-stage process: diagnosis confirmation, prescriber visit, prior authorization, and pharmacy fulfillment. The specifics differ depending on insurance status.

Stage 1: Confirm the diagnosis. Most insurers require evidence of MASH with F2, F3 fibrosis. Acceptable documentation includes a liver biopsy report, a FibroScan (vibration-controlled transient elastography) result showing liver stiffness between 8.0 and 13.9 kPa, or an enhanced liver fibrosis (ELF) score above 9.8. Some plans also accept FIB-4 scores above 1.3 combined with imaging findings.

Stage 2: See a prescriber. Any Montana-licensed MD, DO, NP, or PA with prescriptive authority can write the prescription. You do not need a hepatologist, although referral to one may strengthen a prior authorization appeal.

Stage 3: Submit prior authorization. Nearly every commercial plan requires prior authorization for Rezdiffra. The prescriber's office submits clinical documentation, including fibrosis staging, ALT levels, BMI, and confirmation that the patient does not have decompensated cirrhosis. Turnaround ranges from 48 hours to 14 business days.

Stage 4: Fill at a specialty or 503A pharmacy. Once approved, the prescription is routed to a specialty pharmacy. Patients in Montana can also use a licensed 503A compounding pharmacy if the branded product is unavailable or cost-prohibitive.

Telehealth Access for Montana Residents

Montana permits telehealth prescribing of Rezdiffra under its established telemedicine statutes, making the drug accessible to patients in rural and frontier counties where hepatology offices are scarce.

A telehealth visit for resmetirom typically lasts 20 to 30 minutes. The prescriber reviews your liver labs, imaging, and fibrosis staging. If you already have a FibroScan result or recent biopsy from another provider, most telehealth clinicians will accept those records without repeating the workup.

Montana's Board of Medical Examiners requires that the prescribing provider hold an active Montana license or practice under an interstate compact that Montana recognizes. Several national MASH-focused telehealth platforms meet this requirement. HealthRX connects patients with licensed providers who can evaluate eligibility for resmetirom and manage prior authorization from initial consult through pharmacy fulfillment.

One practical note: telehealth encounters for controlled substances require an in-person visit in some states, but resmetirom is not a controlled substance. It is a prescription-only THR-β agonist with no abuse potential, so a purely virtual visit satisfies Montana law.

Lab Work Required Before and During Treatment

Before any Montana prescriber initiates Rezdiffra, a baseline lab panel is standard. The FDA label and the MAESTRO-NASH protocol both inform the typical workup.

Pre-treatment labs include:

• Comprehensive metabolic panel (CMP), including ALT, AST, albumin, and bilirubin
• Complete blood count (CBC)
• Lipid panel (resmetirom lowers LDL cholesterol; baseline values guide monitoring)
• Thyroid function tests (TSH and free T4), because resmetirom activates THR-β
• FIB-4 index calculation (derived from age, AST, ALT, and platelet count)
• FibroScan or ELF score if liver biopsy has not been performed within the prior 12 months

Monitoring on treatment: The FDA prescribing information recommends checking hepatic function tests periodically. Most prescribers recheck ALT and AST at 12 weeks, then every 3 to 6 months. Lipid panels are rechecked at 12 weeks because resmetirom reduced LDL cholesterol by 13.6% in MAESTRO-NASH, an effect the prescriber should track alongside any statin therapy [1].

Montana has Quest Diagnostics and Labcorp draw sites in Billings, Missoula, Great Falls, Helena, and Bozeman. Patients in smaller communities can use mobile phlebotomy services or local hospital labs with standing orders from their prescriber.

Insurance Coverage and Cost in Montana

The branded list price for Rezdiffra is approximately $47,400 per year. Coverage varies sharply by payer type.

Commercial insurance: Most major insurers (Blue Cross Blue Shield of Montana, Pacific Source, Allegiance) have added Rezdiffra to specialty tiers with prior authorization. Copay after authorization ranges from $0 to $150 per month for commercially insured patients who qualify for Madrigal's copay assistance program.

Montana Medicaid: As of May 2026, Montana Medicaid does not cover Rezdiffra. The state has not added it to its preferred drug list. Patients on Medicaid can apply for Madrigal's patient assistance program, which provides the drug at no cost to qualifying individuals below 400% of the federal poverty level.

Medicare Part D: Coverage decisions vary by plan. A 2024 AACE consensus statement on MASH pharmacotherapy noted that Medicare Part D formulary inclusion for resmetirom remains inconsistent across plan sponsors. Patients should call the number on their Part D card to check formulary status before their prescriber submits authorization.

Cash pay and 503A compounding: For uninsured patients or those denied coverage, compounded resmetirom from a licensed 503A pharmacy may cost significantly less than the branded product. Montana law permits 503A pharmacies to dispense patient-specific compounded medications with a valid prescription. The FDA's compounding quality page outlines the regulatory framework.

Dr. Zobair Younossi, chair of the Global NASH Council, has stated: "The approval of resmetirom marks a turning point for patients with MASH, but access barriers, including formulary delays and prior authorization complexity, risk leaving the highest-need patients untreated" [2].

Prior Authorization: What Montana Prescribers Must Submit

Prior authorization for Rezdiffra in Montana follows a pattern similar to other specialty hepatology drugs. The documentation package that clears most plans includes seven components.

1. ICD-10 code K75.81 (non-alcoholic steatohepatitis)
2. Fibrosis staging documentation (biopsy report, FibroScan printout, or ELF score)
3. Evidence that fibrosis is F2 or F3 (not F0, F1, or F4/decompensated cirrhosis)
4. Baseline ALT and AST values
5. Confirmation the patient does not have decompensated cirrhosis (no ascites, variceal bleeding, or hepatic encephalopathy)
6. Body weight (dose selection depends on weight: 80 mg for patients under 100 kg, 100 mg for 100 kg and above)
7. Documentation that lifestyle modifications have been attempted or are ongoing

Turnaround time after submission averages 5 to 10 business days for commercial plans in Montana. Denials can be appealed with a peer-to-peer review. A letter of medical necessity citing the MAESTRO-NASH results and AASLD guidance strengthens appeals.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy noted that MASH-directed drugs should be covered when fibrosis progression threatens patient outcomes, a principle some Montana prescribers cite in appeal letters for Rezdiffra.

Who Can Prescribe Rezdiffra in Montana

Montana does not restrict Rezdiffra prescribing to specialists. Any clinician with an active DEA registration and Montana prescriptive authority can write the prescription.

That includes MDs, DOs, nurse practitioners (NPs with full practice authority under Montana's APRN statutes), and physician assistants (PAs practicing under a collaboration agreement). Montana granted NPs full practice authority in 2023, removing the prior supervisory requirement. This means a rural NP in, say, Glasgow or Miles City, can independently prescribe resmetirom after confirming the diagnosis and staging.

In practice, many primary care providers in Montana prefer to co-manage MASH patients with a gastroenterologist or hepatologist, especially for the initial fibrosis staging workup. The closest academic hepatology centers are at Billings Clinic and the University of Washington (accessible via telehealth for Montana residents under cross-state licensure agreements).

The American Gastroenterological Association published a clinical care pathway for MASH in 2023 recommending that primary care providers screen at-risk patients using FIB-4 and refer those with indeterminate or high scores for advanced staging. This pathway supports the model where a Montana PCP identifies the patient and collaborates with a specialist for drug initiation.

Pharmacy Fulfillment and Shipping Timelines

Once prior authorization clears, Rezdiffra is dispensed through specialty pharmacies. Most patients in Montana receive their medication by mail within 3 to 7 business days from the authorization date.

National specialty pharmacies that ship to Montana include Accredo, CVS Specialty, and Optum Specialty. These pharmacies handle the enrollment paperwork, benefits verification, and copay assistance application as part of their intake process.

For patients using a Montana-based 503A compounding pharmacy, turnaround depends on the pharmacy's compounding schedule. Typical fill time is 5 to 10 business days after receiving the prescription. Montana's Board of Pharmacy licenses 503A facilities under state rules aligned with FDA Section 503A requirements.

Shipping to rural Montana addresses may add 1 to 2 business days. Resmetirom tablets are stable at room temperature (store at 68°F to 77°F), so cold-chain shipping is not required.

Safety Profile and Monitoring Considerations

Resmetirom's safety data from MAESTRO-NASH showed a manageable adverse event profile. The most common side effects at the 80 mg dose were diarrhea (26.5% vs. 18.9% placebo) and nausea (21.7% vs. 13.6% placebo), with most events rated mild and self-limiting [1].

Serious adverse events occurred at similar rates across the resmetirom and placebo groups (10.9% vs. 12.5%). Drug-induced liver injury signals were not detected. The FDA safety review noted no thyrotoxicosis cases, consistent with resmetirom's selectivity for THR-β over THR-α (the receptor subtype that drives cardiac effects).

Montana prescribers should be aware of two drug interactions. Resmetirom may increase the activity of statins metabolized by OATP1B1/1B3 transporters. The label recommends monitoring for statin-related myopathy. Resmetirom also reduces circulating levels of sex hormone-binding globulin (SHBG), which can affect interpretation of total testosterone assays in patients on concurrent TRT.

Dr. Stephen Harrison, principal investigator of the MAESTRO-NASH trial, noted: "Resmetirom's liver-targeted mechanism produces meaningful fibrosis improvement without the thyroid or cardiac signals you might expect from a hormone receptor agonist" [3].

Transferring a Prescription to Montana

Patients who move to Montana or split time between states can transfer an existing Rezdiffra prescription. Montana accepts prescription transfers from any U.S. state for non-controlled medications.

The process: contact your current specialty pharmacy and request a transfer to a Montana-licensed pharmacy. The receiving pharmacy will verify your Montana address, confirm insurance eligibility in the new state, and may need to re-run prior authorization if your plan's pharmacy benefit manager changed.

If transferring from a state where you used a 503A compounding pharmacy, you will need a new prescription written by a Montana-licensed provider, because 503A compounds require a patient-specific prescription under the dispensing state's law.